Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

NCT03701308 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03701308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03701308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
March 28, 2019
Completion date
October 26, 2026
Enrollment
267 (actual)
Sites
188

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia